1
2
#OpenInnovation
3
4
News & Events
Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement
January 13, 2022
ADVANZ PHARMA gains the rights to develop and commercialize cefepime/enmetazobactam. Read more
Lilly and Foghorn Announce Strategic Collaboration
December 13, 2021
To create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. Read more
OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform
December 8, 2021
Co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors. Read more
5
#knowledgebase
6
7
News & Events
Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement
January 13, 2022
ADVANZ PHARMA gains the rights to develop and commercialize cefepime/enmetazobactam. Read more
Lilly and Foghorn Announce Strategic Collaboration
December 13, 2021
To create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. Read more
OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform
December 8, 2021
Co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors. Read more
8
Portfolio Highlights
#PharmaBiotech
11
Our View
10
Our Focus
12
#PRI
22
Medical Technologies
#Portfolio
14
16
Words from
the CEO
17
Portfolio Highlights
#PharmaBiotech
28
Pharmaceutical Biotech
#Portfolio
15
About Us
34
Biorenewables & Others
#Portfolio
19
WHAT'S TRENDING @ XERAYA
Allecra & Advanz Sign Exclusive Agreement
20
Our Team
21
23
Portfolio Highlights
#Biorenewables
30
Portfolio Highlights
#MedTech
25
26
ARE YOU
The Next
Big Thing?
Submit
A
Proposal
29
36
Career
#Xeraya
35
37
News & Events
Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement
January 13, 2022
ADVANZ PHARMA gains the rights to develop and commercialize cefepime/enmetazobactam. Read more
Lilly and Foghorn Announce Strategic Collaboration
December 13, 2021
To create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. Read more
OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform
December 8, 2021
Co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors. Read more
32
#agro
33
Portfolio Highlights
#Biorenewables
38
Portfolio Highlights
#MedTech
39
40
Contact Us
41
